rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering
Open Access
- 8 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 7 (3) , 256-265
Abstract
Recombinant antibodies have emerged as a promising solution to tackle antigen specificity, enhancement of immunogenic potential and versatile functionalization to treat human diseases. The development of single chain variable fragments (scFv) has helped accelerate treatment in cancers and viral infections, due to their favorable pharmacokinetics and human compatibility. However, designing recombinant antibodies is traditionally viewed as a genetic engineering problem, with phage display and cell free systems playing a major role in sequence selection for gene synthesis. The process of antibody engineering involves complex and time-consuming laboratory techniques, which demand substantial resources and expertise. The success rate of obtaining desired antibody candidates through experimental approaches can be modest, necessitating iterative cycles of selection and optimization. With ongoing advancements in technology, in silico design of diverse antibody libraries, screening and identification of potential candidates for in vitro validation can be accelerated. To meet this need, we have developed rAbDesFlow, a unified computational workflow for recombinant antibody engineering with open-source programs and tools for ease of implementation. The workflow encompasses five computational modules to perform antigen selection, antibody library generation, antigen and antibody structure modeling, antigen-antibody interaction modeling, structure analysis, and consensus ranking of potential antibody sequences for synthesis and experimental validation. The proposed workflow has been demonstrated through design of recombinant antibodies for the ovarian cancer antigen Mucin-16 (CA-125). This approach can serve as a blueprint for designing similar engineered molecules targeting other biomarkers, allowing for a simplified adaptation to different cancer types or disease-specific antigens.Keywords
Funding Information
- Anusandhan National Research Foundation (IPA/2021/000147)
This publication has 63 references indexed in Scilit:
- Deep learning-based method for predicting and classifying the binding affinity of protein-protein complexesBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2023
- Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor markerProteins: Structure, Function, and Bioinformatics, 2022
- Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of ConcernInfectious Diseases and Therapy, 2021
- HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Why recombinant antibodies — benefits and applicationsCurrent Opinion in Biotechnology, 2019
- Web‐accessible molecular modeling with Rosetta: The Rosetta Online Server that Includes Everyone (ROSIE)Protein Science, 2017
- Using PyMOL as a platform for computational drug designWIREs Computational Molecular Science, 2017
- Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage displayProteomics – Clinical Applications, 2016
- Evolution of Antibodies In Vitro by Ribosome Display2012
- OC-125 as a diagnostic aid in the cytological evaluation of ascitic cells in patients with ovarian carcinomaVirchows Archiv, 1991